Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate?

Grasso LF, Pivonello R, Colao A.

Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):288-94. doi: 10.1097/MED.0b013e328354af67. Review.

PMID:
22627686
2.

Somatostatin analogs as primary medical therapy for acromegaly.

Danoff A, Kleinberg D.

Endocrine. 2003 Apr;20(3):291-7. Review.

PMID:
12721510
3.

Medical therapy for acromegaly.

Newman CB.

Endocrinol Metab Clin North Am. 1999 Mar;28(1):171-90. Review.

PMID:
10207690
4.

Acromegaly.

Scacchi M, Cavagnini F.

Pituitary. 2006;9(4):297-303. Review.

PMID:
17077948
5.

The effects of somatostatin analogs on biochemical parameters in acromegaly.

Liuzzi A, Marzullo P.

J Endocrinol Invest. 2003;26(8 Suppl):46-9. Review. No abstract available.

PMID:
15233212
6.

The role of somatostatin agonistic analogs in the treatment of acromegaly.

Tolis G.

Metabolism. 1996 Aug;45(8 Suppl 1):109-10. Review.

PMID:
8769400
7.

Efficacy and safety of radiotherapy in acromegaly.

González B, Vargas G, Espinosa-de-los-Monteros AL, Sosa E, Mercado M.

Arch Med Res. 2011 Jan;42(1):48-52. doi: 10.1016/j.arcmed.2011.01.004.

PMID:
21376263
8.

Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.

Bacigaluppi S, Gatto F, Anania P, Bragazzi NL, Rossi DC, Benvegnu G, Nazzari E, Spaziante R, Giusti M, Ferone D, Zona G.

Endocrine. 2016 Mar;51(3):524-33. doi: 10.1007/s12020-015-0619-5. Epub 2015 May 17.

PMID:
25982150
9.
10.

Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.

Gola M, Doga M, Bonadonna S, Mazziotti G, Vescovi PP, Giustina A.

Pituitary. 2006;9(3):221-9. Review.

PMID:
17036195
11.

An update on treatment strategies for acromegaly.

Katznelson L.

Expert Opin Pharmacother. 2008 Sep;9(13):2273-80. doi: 10.1517/14656566.9.13.2273 . Review.

PMID:
18710352
12.

Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.

Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E.

N Engl J Med. 1985 Dec 19;313(25):1576-80.

PMID:
2866445
13.

Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.

Jallad RS, Musolino NR, Salgado LR, Bronstein MD.

Clin Endocrinol (Oxf). 2005 Aug;63(2):168-75.

PMID:
16060910
14.

New formulations and approaches in the medical treatment of acromegaly.

Debono M, Newell-Price J.

Curr Opin Endocrinol Diabetes Obes. 2010 Aug;17(4):350-5. doi: 10.1097/MED.0b013e32833ab099. Review.

PMID:
20502324
15.

Pegvisomant: new preparation. A last resort in acromegaly.

[No authors listed]

Prescrire Int. 2005 Feb;14(75):10-3.

PMID:
15751152
16.

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.

Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A.

J Clin Endocrinol Metab. 2005 Jul;90(7):4405-10. Epub 2005 Apr 12.

PMID:
15827109
17.

Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates.

Losa M, Mortini P, Urbaz L, Ribotto P, Castrignan├│ T, Giovanelli M.

J Neurosurg. 2006 Jun;104(6):899-906.

PMID:
16776333
18.

Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.

McKeage K, Cheer S, Wagstaff AJ.

Drugs. 2003;63(22):2473-99. Review.

PMID:
14609359
19.

Long-term management of acromegaly with sandostatin.

Tolis G.

Horm Res. 1988;29(2-3):112-4.

PMID:
2900189
20.

Combined treatment of somatostatin analogues with pegvisomant in acromegaly.

Franck SE, Muhammad A, van der Lely AJ, Neggers SJ.

Endocrine. 2016 May;52(2):206-13. doi: 10.1007/s12020-015-0810-8. Epub 2015 Dec 10. Review.

Supplemental Content

Support Center